Page 25 - Medication Guide News Today

– Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of... | April 19, 2023

The FDA approved a psychotropic drug containing a sensor that transmits compliance information to doctors, sparking fear and controversy.

QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic Expanded...

The FDA has updated the prescribing information for all opioid analgesics in order to provide additional guidance on how to safely prescribe these medications.

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this...

/PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final...

The FDA has updated the prescribing information for all opioid analgesics in order to provide additional guidance on how to safely prescribe these medications.

Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant... | April 16, 2023

RAHWAY, N.J.--(BUSINESS WIRE)--Apr 16, 2023--

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL... | April 16, 2023